Palbociclib for recurrent ovarian cacner – pro
This is a late line of therapy and the standard of care does not exist in this situation. However, Ibrance is supported by the literature. There is emerging data that CDK4/6 may be effective in metastatic ovarian cancer. Besides palbociclib or our case, another CDK4/6 inhibitor, ribociclib has also been explored in gynecological malignancies. A phase 2 trial by Colon-Otero et al treated patients with relapsed estrogen-receptor positive ovarian and endometrial cancers. Among the 20 patients with ovarian cancer, this trial reported 50% progression-free survival at 12 months, and a similar 55% for endometrial cancer. Besides case report, a phase II study by Gottfried et al showed that CDK4/6 inhibition with palbociclib was well tolerated and demonstrated single-agent activity in heavily pretreated unselected Ovarian Cancer patients.
Lee DW, Ho GF. Palbociclib in the treatment of recurrent ovarian cancer. Gynecol Oncol Rep. 2020 Sep 1;34:100626
Colon-Otero G., Weroha S.J., Zanfagnin V., Foster N.R., Asmus E., Hendrickson A.E. Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. J. Clin. Oncol. 2019;37(15):5510.
Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P. Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. Cancer Biol Ther. 2020;21(3):197-202.
Dall’Acqua, A.; Bartoletti, M.; Masoudi-Khoram, N.; Sorio, R.; Puglisi, F.; Belletti, B.; Baldassarre, G. Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. Cancers 2021